ANOS1

Across TCGA pan-cancer cohorts, ANOS1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ANOS1 data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ANOS1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ANOS1 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

PDAC, GBM, and HNSC are the cancer types where ANOS1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.651	0.848	.009	45	view →
GBM	DFS	Tertile	All	0.565	0.245	.006	10	view →
HNSC	DFS	Median	IV	0.477	0.930	.009	8	view →
LUAD	DFS	Median	III,IV	0.504	0.977	.005	5	view →
LSCC	DFS	Quartile	II,III,IV	0.386	1.000	.024	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ANOS1–PDAC (DFS)

Open the PDAC breakdown →